You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 30, 2018

Vietnam: Examining the NOIP’s Approach to Post-Grant Correction of Patents

Managing Intellectual Property

In Vietnam, granted patents can be amended in certain circumstances under provisions found in the Law on Intellectual Property (IP Law). For example, Article 97 of the IP Law gives a patent owner the right to request correction of errors made by the National Office of Intellectual Property (NOIP) in a granted patent.

The law is silent regarding correction of errors made by other parties, such as the patent owner itself, or its local patent agent. However, to ensure the accuracy of a patent, common sense dictates that correctable errors should not be limited to those made by the NOIP, but should extend to any other obvious errors.

In practice, a patent owner can request the NOIP to correct obvious errors that are not clearly the fault of the NOIP. However, there is no definition in Vietnamese legal documents of what constitutes an “obvious error.” A recent case involving a European pharmaceutical company brought this issue to the forefront.

Post-Grant Correction Rejected

The company in question holds a Vietnamese patent that was granted nearly a decade ago for a compound for the treatment of a medical condition. The company is now battling infringing generic products in the Vietnam market, but faced a temporary setback when it discovered, in the course of litigation, that its patent had an error in the chemical formula (structural formula) of the compound, although the compound name was written correctly.

It is worth noting that the patent originated from a foreign priority document, which was enclosed with the Vietnam application, in which the correct structural formula and compound name were shown. It is likely that the error was introduced during the translation of the patent specification into Vietnamese by a local patent agent.

As a result of this error, the company recognized that enforcement efforts could be hindered, as generic producers could argue that they were not technically infringing the patent, because the compound in their products was not the same as the patented compound, based on the (erroneous) structural formula in a claim of the granted patent.

The company thus proactively petitioned for a correction of the granted patent, reasoning that the error in the structural formula was obvious and should have been readily apparent to a person having ordinary skill in the art. The examiner in charge of the patent certainly should have had the capacity to discover the error before granting the patent, having reviewed the priority document and the corresponding patents issued previously by other patent offices, which all showed the correct structural formula. The NOIP, however, refused to correct the patent, claiming that the error was not obvious.

What Makes an Error Obvious?

The NOIP’s refusal notice referred to some concepts of obvious errors in the case law of the Boards of Appeal of the European Patent Office (EPO), and also stated that the NOIP considers these concepts to be appropriate. Specifically, the NOIP cited Point 4.2 in the Case Law, that for a correction to be made, it must be established that:

it is obvious that an error is in fact present in the document filed with the EPO, the incorrect information having to be objectively recognizable [emphasized in the NOIP’s notice] by the skilled person using common general knowledge.

The NOIP argued that if the patent owner did not notice the error within the two-year patent examination period, let alone for nearly 10 years thereafter, it could hardly be considered “obvious.” In addition, the same error appeared in other applications and patents of the company related to the compound.

While the patent application in question referred to the correct description in the EP patent, the incorrect structural formula consistently appeared throughout the summary, description, and claims of the Vietnamese application itself, and the NOIP further asserted that it had no obligation to consider other documents, referring to Point 4.2.1 of the case law:

On the other hand, documents, even if they were filed together with the European patent application, such as priority documents and the abstract may not be used.

Outlook

The arguments in the NOIP’s refusal notice signal that the NOIP intends to follow the EPO’s practice regarding obvious errors and their corrections (though it is debatable that the EPO would have come to the same conclusion in a similar situation). Historically, however, the NOIP’s practice has not always been consistent, and it is unclear to what extent patent correction will be allowed in the future. To ensure their patent rights in Vietnam, practitioners and applicants would be well advised to review their applications very carefully, and rely only on reputable, experienced IP agents, with the most accurate translation capacity, for patent prosecution, to avoid unexpected consequences.

RELATED INSIGHTS​ 

February 25, 2026
Tilleke & Gibbins has updated the Vietnam chapter in the newly released Licensing 2026 guide, published by Lexology Panoramic. The comparative guide provides companies and other interested readers with information on licensing law and practice in various countries around the world. Licensing 2026 provides detailed information on the following topics: Restrictions, laws and licensing arrangements Intellectual property issues: Paris Convention for the Protection of Industrial Property, contesting the validity of licensor’s IP rights, invalidity and expiry of IP rights, security interests, proceedings against third parties, sublicensing, jointly owned IP, first to file, scope of patent protection, trade secrets, copyright Software licensing: Perpetual licensing, legal requirements, user restrictions Royalties and payments, currency conversion, and taxes: Relevant legislation, restrictions, taxation of foreign licensors Competition law issues: Restrictions on trade, legal restrictions, and IP-related court rulings Indemnification, disclaimers, and damages: Prevalence and enforceability of indemnity provisions and contractual waivers of damages Termination: Right to terminate, impact of termination Bankruptcy: Impact of licensee or licensor bankruptcy Dispute resolution: Governing law, arbitration, enforceability, injunctive relief, contractual waivers The Vietnam chapter is available below as a PDF. Readers can gain 30 days of complementary access to the full Licensing 2026 guide and the rest of Lexology Panoramic’s varied offerings through this link.
January 30, 2026
On December 26, 2025, the government of Vietnam promulgated Decree No. 341/2025/ND-CP on administrative sanctions for violations of copyright and related rights (Decree 341), with an effective date of February 15, 2026. The new decree replaces Decree No. 131/2013/ND-CP, as amended, and represents the first comprehensive revision of the administrative enforcement framework in this area in eight years. Legislative Context and Objectives Decree 341 reflects Vietnam’s evolving copyright and related-rights framework, particularly in light of the country’s commitments under bilateral, regional, and multilateral treaties governing the digital environment. While the decree retains a number of provisions from the previous regime, it also introduces significant amendments to infringing acts, penalty thresholds, remedial measures, and enforcement procedures. The primary objectives of the new decree are to (i) enhance the deterrent effect of administrative sanctions; (ii) harmonize sanctions with the 2025 amendments to the Law on Intellectual Property and criminal law principles; and (iii) address enforcement challenges arising from online and cross-border exploitation of copyrighted works. Expanded Scope of Sanctionable Subjects Under Decree 341, administrative sanctions apply not only to Vietnamese entities committing infringing acts within Vietnam, but also to Vietnamese and foreign entities that commit acts of infringement on the internet where the protected content is accessed, consumed, or exploited by users in Vietnam. This expansion reflects the realities of cross-border digital exploitation. However, the decree does not yet provide precise definitions of key terms such as “users” or “consumers” of digital content in Vietnam, which may require further regulatory clarification. Monetary Penalties and Penalty Structure The statutory maximum fines remain unchanged, at VND 250 million for individuals and VND 500 million for organizations, but the penalty framework is substantially restructured. Fines are now calibrated based on three core criteria: (i) the amount of illegal profit obtained; (ii) the level of
January 30, 2026
Vietnam’s Intellectual Property (IP) Law, despite being amended in 2022, underwent another significant revision at the end of 2025. The latest amendment aimed to address five major policy objectives set by the Vietnamese government, including promoting innovation, digital transformation, and international integration. Among the most notable changes in the 2025 IP Law, which takes effect on 1 April 2026, is the expansion of industrial design protection under Article 4.13. The revised definition now includes partial designs and intangible designs, marking a transformative shift in Vietnam’s industrial design regime. This change has particularly significant implications on designs classified under Class 32 of the Locarno Classification—which covers graphic designs, logos, ornamentation, surface patterns, arrangements, and other intangible products. These designs, previously excluded from protection in Vietnam, are now recognized under the new legal framework. Background: Status of Class 32 Designs Before 2026 Th Intellectual Property Office of Vietnam currently applies the 13th edition of the Locarno Classification for industrial design filings. However, not all classes in this system have historically been eligible for protection. Under the 2022 IP Law, Class 32 designs were explicitly excluded based on the following legal grounds: Definition under Article 4.13 (2022 IP Law): “An industrial design is the external appearance of a product or a component for assembly into a complex product, expressed in shapes, lines, colors, or a combination thereof, and visible during the exploitation of the product’s utility or the complex product.” Product requirements under Article 21.2 of Circular 23/2023/TT-BKHCN: A product is defined as an object, a tool, a device, or means, manufactured by industrial or handicraft methods, with clear structure and function. A component for assembly into a complex product must be capable of independent circulation and detachable from the complex product. Based on these definitions, Class 32 designs, such as graphical
December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted